Hydroxyethyl starch versus other plasma volume expanders: a review of the clinical and cost-effectiveness, and guidelines for use
CADTH
Record ID 32014000160
English
Authors' recommendations:
Twelve meta-analyses, two clinical guidelines, and one cost-effectiveness study were included in the review. The available evidence indicates the use of hydroxyethyl starch is associated with increased risk of mortality and renal dysfunction when used for fluid resuscitation in critically ill patients and patients with severe sepsis. The available evidence suggests that the use of hydroxyethyl starch in patients undergoing surgery may be associated with increased risk of bleeding and reoperation due to bleeding. One cost-effectiveness analysis showed that hydroxyethyl starches were less cost-effective, compared with albumin, when used for fluid resuscitation in sepsis patients.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/jun-2013/RC0451%20-%20Hydroxyethyl%20Starch%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Hydroxyethyl Starch Derivatives
- Plasma Volume
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.